Combination analyses of anti-cancer drugs on human neuroendocrine tumor cell lines

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 1, 2009, Pages 5-12

  Larsson, Dhana E ^a   Hassan, Sadia ^a   Larsson, Rolf ^a   Öberg, Kjell ^a   Granberg, Dan ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Chemotherapy; Combination; Drug sensitivity; Neuroendocrine tumors

Indexed keywords

ANTINEOPLASTIC AGENT; BREFELDIN A; CGP 74514A; DOCETAXEL; DOXORUBICIN; EMETINE; ETOPOSIDE; NSC 95397; OXALIPLATIN; SANGUINARINE; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; TUMOR CELL LINE;

2-AMINOPURINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRONCHIAL NEOPLASMS; CARCINOID TUMOR; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; EMETINE; HUMANS; NAPHTHOQUINONES; NEUROENDOCRINE TUMORS; PANCREATIC NEOPLASMS;

EID: 70349613212     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-0997-6     Document Type: Article

References (28)

1. BI Gustafsson M Kidd A Chan MV Malfertheiner IM Modlin 2008 Bronchopulmonary neuroendocrine tumors Cancer 113 5 21 18473355 10.1002/cncr.23542 1:CAS:528:DC%2BD1cXos1yhsbg%3D (Pubitemid 351976381)
2. MB Beasley E Brambilla WD Travis 2005 The 2004 World Health Organization classification of lung tumors Semin Roentgenol 40 90 97 15898407 10.1053/j.ro.2005.01.001 (Pubitemid 40417889)
3. D Granberg B Eriksson E Wilander P Grimfjard ML Fjallskog K Oberg B Skogseid 2001 Experience in treatment of metastatic pulmonary carcinoid tumors Ann Oncol 12 10 1383 1391 11762808 10.1023/A:1012569909313 1:STN:280: DC%2BD38%2FjsFaluw%3D%3D (Pubitemid 33100242)
4. K Oberg 1999 Neuroendocrine gastrointestinal tumors-a condensed overview of diagnosis and treatment Ann Oncol 10 Suppl 2 S3 S8 10399026 10.1023/A:1027336026601
5. MH Shah D Young HL Kindler I Webb B Kleiber J Wright M Grever 2004 Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors Clin Cancer Res 10 6111 6118 15447997 10.1158/1078-0432.CCR-04-0422 1:CAS:528:DC%2BD2cXnvVOjsrc%3D (Pubitemid 39287516)
6. MB Beasley FB Thunnissen E Brambilla P Hasleton R Steele SP Hammar TV Colby M Sheppard Y Shimosato MN Koss R Falk WD Travis 2000 Pulmonary atypical carcinoid: predictors of survival in 106 cases Hum Pathol 31 1255 1265 11070119 10.1053/hupa.2000.19294 1:STN:280:DC%2BD3M%2FksF2kuw%3D%3D (Pubitemid 30810092)
7. CG Jonnakuty SG Mezitis 2007 Pulmonary atypical carcinoid tumor with metastatic involvement of the pituitary gland causing functional hypopituitarism Endocr Pract 13 291 295 17599862
8. CG Moertel M Lefkopoulo S Lipsitz RG Hahn D Klaassen 1992 Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma N Engl J Med 326 8 519 523 1310159 1:STN:280:DyaK387itlejuw%3D%3D
9. AD McCollum MH Kulke DP Ryan LN Shulman RJ Mayer S Bartel S Bartel CS Fuchs 2004 Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors Am J Clin Oncol 27 485 488 15596916 10.1097/01.coc.0000135343.06038.eb 1:CAS:528:DC%2BD2cXps1altbk%3D (Pubitemid 39371944)
10. TC Chou P Talalay 1984 Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 27 55 6382953 10.1016/0065-2571(84)90007-4 1:CAS:528: DyaL2cXktlaksLk%3D
11. DE Larsson H Lovborg L Rickardson R Larsson K Oberg D Granberg 2006 Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines Anticancer Res 26 6B 4125 4129 17201123 1:CAS:528:DC%2BD2sXpslChsA%3D%3D
12. M Wink T Schmeller B Latz-Brüning 1998 Modes of action of allelochemical alkaloids: interaction with neuroreceptors, DNA, and other molecular targets J Chem Ecol 24 1881 1937 10.1023/A:1022315802264 1:CAS:528:DyaK1cXnvVCnt7w%3D
13. R Larsson J Kristensen C Sandberg P Nygren 1992 Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA) Int J Cancer 50 177 185 1730510 10.1002/ijc.2910500204 1:STN:280:DyaK387ht1elsw%3D%3D
14. L Rickardson M Fryknas S Dhar H Lovborg J Gullbo M Rydaker P Nygren MG Gustafsson R Larsson A Isaksson 2005 Identification of molecular mechanisms for cellular drug resistance by combining drug activity and gene expression profiles Br J Cancer 93 483 492 16012520 10.1038/sj.bjc.6602699 1:CAS:528: DC%2BD2MXnvFymtLg%3D (Pubitemid 43080025)
15. F Valeriote H Lin 1975 Synergistic interaction of anticancer agents: a cellular perspective Cancer Chemother Rep 59 5 895 900 1203896 1:STN:280:DyaE28%2FptVanug%3D%3D
16. PA Kosmidis 2004 Treatment of carcinoid of the lung Curr Opin Oncol 16 146 149 15075907 10.1097/00001622-200403000-00011 (Pubitemid 38402528)
17. K Oberg 2001 Chemotherapy and biotherapy in the treatment of neuroendocrine tumours Ann Oncol 12 Suppl 2 S111 S114 11762335 10.1023/A:1012465801251
18. M Ducreux E Baudin M Schlumberger 2002 Treatment strategy of neuroendocrine tumors Rev Prat 52 3 290 296 11925720
19. RR Warner 2003 Carcinoid case presentation and discussion: the American perspective Endocr Relat Cancer 10 489 496 14713263 10.1677/erc.0.0100489 1:STN:280:DC%2BD2c%2Fhs1aktw%3D%3D (Pubitemid 38094887)
20. MH Kulke H Kim K Stuart JW Clark DP Ryan M Vincitore RJ Mayer CS Fuchs 2004 A phase II study of docetaxel in patients with metastatic carcinoid tumors Cancer Invest 22 353 359 15493355 10.1081/CNV-200029058 1:CAS:528: DC%2BD2cXmvF2jurk%3D
21. SM Ansell HC Pitot PA Burch LK Kvols MR Mahoney J Rubin 2001 A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors Cancer 91 1543 1548 11301403 10.1002/1097-0142(20010415)91:8<1543::AID- CNCR1163>3.0.CO;2-N 1:CAS:528:DC%2BD3MXjt1Srsbg%3D (Pubitemid 32319266)
22. A Vogt PR McDonald A Tamewitz RP Sikorski P Wipf JJ Skoko 3rd JS Lazo 2008 A cell-active inhibitor of mitogen-activated protein kinase phosphatases restores paclitaxel-induced apoptosis in dexamethasone-protected cancer cells Mol Cancer Ther 7 330 340 18245669 10.1158/1535-7163.MCT-07-2165 1:CAS:528:DC%2BD1cXitVSiu7w%3D (Pubitemid 351302526)
23. M Cazales R Boutros MC Brezak S Chaumeron G Prevost B Ducommun 2007 Pharmacologic inhibition of CDC25 phosphatases impairs interphase microtubule dynamics and mitotic spindle assembly Mol Cancer Ther 6 318 325 17237290 10.1158/1535-7163.MCT-06-0299 1:CAS:528:DC%2BD2sXmsVaksA%3D%3D (Pubitemid 46206696)
24. EW Street 1972 Cyclophosphamide plus emetine in lung cancer Lancet 2 7773 381 382 4114753 10.1016/S0140-6736(72)91771-0 1:STN:280:DyaE383ktVKkuw%3D%3D
25. M Moller K Herzer T Wenger I Herr M Wink 2007 The alkaloid emetine as a promising agent for the induction and enhancement of drug-induced apoptosis in leukemia cells Oncol Rep 8 737 744
26. AB Combs D Acosta 1990 Toxic mechanisms of the heart: a review Toxicol Pathol 18 4 Pt 1 583 596 2091237 1:CAS:528:DyaK3MXltVOrsLs%3D
27. MM Pires CA Hrycyna J Chmielewski 2006 Bivalent probes of human multidrug transporter P-glycoprotein Biochemistry 45 11695 11702 16981729 10.1021/bi0608109 1:CAS:528:DC%2BD28XovVahtrg%3D (Pubitemid 44454017)
28. BR Selvi SK Pradhan J Shandilya C Das BS Sailaja GN Shankar SS Gadad A Reddy D Dasgupta TK Kundu 2009 Sanguinarine interacts with chromatin, modulates epigenetic modifications, and transcription in the context of chromatin Chem Biol 16 2 203 216 10.1016/j.chembiol.2008.12.006